Simplify's Biopharma Portfolio Adjustments.
Simplify Asset Management Increases Benitec Biopharma Stake by 272%, Adjusts Other Biopharma Holdings.
Anonymous
Key Points
1
52.19% of Benitec Biopharma stock is owned by hedge funds and other institutional investors, underscoring the institutional-heavy ownership backdrop against Simplify Asset Management's added BNTC stake.
2
Approximately 99.41% of Eyepoint Pharmaceuticals stock is owned by hedge funds and other institutional investors, highlighting the outsized role of institutions even as Simplify trimmed its EYPT position to 326,142 shares.
3
Palisade Bio has institutional ownership of about 11.79%, with Simplify’s 350,000-share new stake representing roughly 0.21% of the company.
4
Vor Biopharma shows very high institutional ownership at 97.29%, while Simplify initiates a 53,510-share stake (~$955,000); notable insider activity includes Ra Capital Management selling 165,150 shares in late April (about $2.6 million), with insiders overall owning about 0.27%.
Simplify Asset Management nearly tripled its stake in Benitec Biopharma (BNTC) during the first quarter of 2026, buying 411,079 additional shares for a 271.9% increase, according to WatchlistNews. The firm now holds 562,242 shares of the clinical-stage gene therapy company, worth roughly $5.99 million and equal to about 1.6% of Benitec's outstanding stock.
The move is part of a broader reshuffling by Simplify across several small biopharma names. The firm also opened new positions in Palisade Bio and Vor Biopharma, while cutting its EyePoint Pharmaceuticals stake by 13.1%. The trades were disclosed in Simplify's Q1 2026 Form 13F filing with the SEC on April 27.
Simplify's SURI ETF Drives Biopharma Buying Spree
The trades flow through the Simplify Propel Opportunities ETF (SURI), an actively managed fund launched in February 2023. Propel Bio Management, LLC serves as the fund's sub-adviser. It is led by Managing General Partner Leen Kawas, a specialist in life sciences investing. Simplify handles derivatives-based hedging and trade execution on top of Propel's stock picks.
Simplify manages roughly $6.52 billion in 13F portfolio assets. Its co-founders, CEO Paul Kim and CIO David Berns, built the firm around packaging institutional-grade strategies inside liquid ETF structures. The SURI ETF gives retail investors access to a curated basket of sub-cap clinical-stage biotechs that most funds ignore.
Benitec Surges in Portfolio as Gene Therapy Bet Grows
Simplify's 272% bump in BNTC is its boldest move this quarter. Benitec focuses on gene therapy — technology that "silences and replaces" defective genes. Institutions own 52.19% of Benitec's shares overall, a relatively modest figure for a biotech. Simplify's 1.6% slice makes it a meaningful holder in a thinly owned stock.
At the same time, Simplify trimmed EyePoint Pharmaceuticals by 49,122 shares, ending the quarter with 326,142 shares worth about $4.2 million. EyePoint makes micro-insert drug delivery devices for eye diseases. Unlike Benitec, EyePoint is dominated by institutions, which own a striking 99.41% of its shares, according to WatchlistNews.
New Positions in Palisade and Vor Signal Fresh Conviction
Simplify opened a brand-new 350,000-share stake in Palisade Bio (PALI), valued at roughly $612,000. Palisade develops treatments for gastrointestinal inflammation and tissue repair. Institutions own only 11.79% of Palisade, meaning Simplify's new stake alone represents about 0.21% of the entire company — a large footprint for such a lightly held stock.
The firm also bought 53,510 shares of Vor Biopharma (VOR) for about $955,000. Vor recently pivoted from cancer cell therapy to autoimmune diseases, centering its pipeline on a drug called telitacicept. Institutions own 97.29% of VOR. Simplify's entry is small at 0.11% of the company, but it arrives at a notable moment.
RA Capital's Massive VOR Sell-Off Complicates the Picture
Just weeks after Simplify bought into Vor Biopharma, insider firm RA Capital Management began dumping its shares at scale. RA Capital sold 458,411 shares on April 17 for roughly $7.46 million, then unloaded another 171,963 shares on April 20 for $2.71 million, and 165,150 more shares on April 22 for about $2.60 million. RA Capital holds a board seat at Vor through Managing Director Dr. Andrew Levin.
The selling by a board-level insider raises questions about Simplify's timing. Analysts at WatchlistNews note that despite the insider sales, Vor still holds more cash than debt — a sign some see as technical undervaluation. Overall insider ownership at VOR stands at just 0.27%, meaning most of the pressure on the stock comes entirely from institutional block trades.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
46
Articles
25
Reach
71
A
AnonymousAuthor
